Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M554Revenue $M9.8Net Margin (%)-1,391.7Z-Score3.2
Enterprise Value $M351EPS $-3.4Operating Margin %-1,371.2F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-1,391.7Higher ROA y-yY
Price/Book2.210-y EBITDA Growth Rate %-4.9Quick Ratio6.7Cash flow > EarningsY
Price/Sales55.15-y EBITDA Growth Rate %28.7Current Ratio6.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-44.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-51.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M41.3ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 13.42-25%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 13.42-68%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 13.42-136%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 13.42-89%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 13.42-120%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 13.42-186%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 13.42-115%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 13.42-99%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 13.4255%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 13.4262%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 13.4241%Add 50.00%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 13.4228%New holding200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.8216.07view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.8216.07view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95-1.65view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.569.24view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-62.96view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-60.77view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-58.02view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-55.88view
Price Ben GilDirector 2013-08-19Buy500$31.18-56view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-64.36view

Press Releases about SRPT :

    Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Our Partners
    Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015 - ZACKS

    More From Other Websites
    Santhera -- A Duchenne Drug With Positive Study Results That Few Know About Apr 23 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Apr 20 2015
    Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015
    4 Stocks Rising on Unusual Volume to Trade for Breakouts Apr 06 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 02 2015
    Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog Apr 01 2015
    Stock Pops & Drops: SRPT, KORS, DAL & GPRO Apr 01 2015
    Sarepta Therapeutics CEO Resigns Amid Tumult With the FDA Apr 01 2015
    Sarepta Therapeutics: Why CEO Resignation is Good News Apr 01 2015
    Sarepta CEO Quits; Successor Pledges to Work Better With FDA Apr 01 2015
    Stock Futures Down, Not Diving; Jobs Data Slip To 11-Month Low Apr 01 2015
    Sarepta Therapeutics CEO Chris Garabedian resigns Apr 01 2015
    Sarepta shares rally 10% as company names interim CEO Apr 01 2015
    Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Call... Apr 01 2015
    Early movers: SHLD, WMT, GDDY, AAPL & more Apr 01 2015
    An Interview With Sarepta's New CEO Mar 31 2015
    Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame Mar 31 2015
    Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and... Mar 31 2015
    Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and... Mar 31 2015
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK